MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease

The relationship between monoamine oxidase B (MAOB) A644G polymorphism and Parkinson disease risk: a meta-analysis

(2017) Ying Liu et al.   ANNALS OF SAUDI MEDICINE

How close are we to individualized medicine for Parkinson’s disease?

(2016) Hee Jin Kim et al.   Expert Review of Neurotherapeutics

Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease

(2016) Vivian Altmann et al.   PHARMACOGENOMICS

How close are we to individualized medicine for Parkinson’s disease?

(2016) Hee Jin Kim et al.   Expert Review of Neurotherapeutics

Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease

(2015) Julia Muellner et al.   PARKINSONISM & RELATED DISORDERS

Epidemiology and etiology of Parkinson’s disease: a review of the evidence

(2011) Karin Wirdefeldt et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease

(2011) Lonneke M.L. de Lau et al.   MOVEMENT DISORDERS

From reinforcement learning models to psychiatric and neurological disorders

(2011) Tiago V Maia et al.   NATURE NEUROSCIENCE

The scientific and clinical basis for the treatment of Parkinson disease (2009)

(2009) C. W. Olanow et al.   NEUROLOGY

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinsonʼs disease, levodopa treatment response, and complications

(2008) Monika Bialecka et al.   Pharmacogenetics and Genomics